Bausch & Lomb Technolas
This article was originally published in The Gray Sheet
Executive Summary
Expanded indication for 217A excimer laser system - to treat hyperopia with or without astigmatism - is undergoing final labeling review by FDA, B&L notes Oct. 18. Firm also announces U.S. debut of its SofLens multi-focal contact lens. Cleared via 510(k) in May, the presbyopic lens will allow improved fit compared with B&L's Occasions multi-focal lenses, which provide near and far vision in different zones. Corporate revenues for the third quarter (ended Sept. 28) are $466.7 mil., up 11%, including a 13% advance in contact lens sales, B&L reports Oct. 17. Earnings of $9.4 mil. are off 59.6%, including $16.7 mil. in after-tax restructuring charges and write-offs...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.